CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Identify where to find high risk investments that offer potential for high returns. Explore various avenues to enhance your portfolio.
27,969 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Investing in rare earths is a long game tied to U.S. policy, global demand, and the pace of production. This guide co...
A political wave can tilt market sentiment, especially around inflation. This article explains why the claim 'preside...
A small, overlooked quantum company could ride a wave of lab-to-market commercialization. This guide breaks down why ...
A five-year restraining order against a persistent admirer shows how safety, law, and money intersect. Learn practica...
BTCC reports rapid growth and a broader product slate in 2026, while safety, risk controls, and regulatory compliance...
In mid-June, hawkish central bank signals set the tone for global markets. The FTSE 100 faltered while the Nikkei 225...
February delivered a sharp 21.4% drop for BigBear.AI, widening concerns about AI stocks. This guide breaks down the d...
Tesla has fallen about 14% this year, but a dip isn’t a doom signal. Here’s a clear framework to decide if now is the...
February brought a sharp move for Applied Digital, with the stock sliding around 19%. This article breaks down what d...
A landmark ruling reshapes how investors view the Fed's independence and policy credibility. This could translate int...
Urban air mobility could redefine city travel, and Archer Aviation sits at the center of that promise. This guide bre...